Baker Tilly Wealth Management
VRTX icon

Baker Tilly Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Baker Tilly Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.75M Buy
3,347
+32
+1% +$16.4K 0.34% 53
2026
Q2 		$1.65M Buy
3,315
+127
+4% +$56.3K 0.35% 55
2026
Q1 		$1.42M Buy
3,188
+79
+3% +$36.8K 0.35% 52
2025
Q4 		$1.41M Buy
3,109
+28
+0.9% +$12.1K 0.35% 52
2025
Q3 		$1.21M Buy
3,081
+173
+6% +$72.3K 0.27% 62
2025
Q2 		$1.29M Sell
2,908
-80
-3% -$36.9K 0.46% 36
2025
Q1 		$1.45M Buy
2,988
+1,092
+58% +$509K 0.57% 30
2024
Q4 		$764K Sell
1,896
-393
-17% -$182K 0.3% 81
2024
Q3 		$1.06M Buy
2,289
+401
+21% +$193K 0.47% 49
2024
Q2 		$885K Sell
1,888
-880
-32% -$382K 0.36% 63
2024
Q1 		$1.16M Buy
2,768
+42
+2% +$17.8K 0.21% 112
2023
Q4 		$1.11M Sell
2,726
-569
-17% -$210K 0.18% 125
2023
Q3 		$1.15M Sell
3,295
-6,439
-66% -$2.25M 0.19% 115
2023
Q2 		$3.43M Buy
9,734
+249
+3% +$83.9K 0.36% 65
2023
Q1 		$2.99M Sell
9,485
-274
-3% -$82.2K 0.34% 65
2022
Q4 		$2.82M Buy
9,759
+880
+10% +$268K 0.35% 71
2022
Q3 		$2.57M Buy
8,879
+498
+6% +$143K 0.35% 65
2022
Q2 		$2.36M Sell
8,381
-901
-10% -$241K 0.31% 72
2022
Q1 		$2.42M Buy
9,282
+1,510
+19% +$358K 0.27% 79
2021
Q4 		$1.71M Buy
7,772
+1,081
+16% +$210K 0.18% 115
2021
Q3 		$1.21M Buy
+6,691
New +$1.31M 0.16% 131

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $59.1B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Baker Tilly Wealth Management's VRTX Position: Q3 2026 in Review

Baker Tilly Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.97% in Q3 2026, buying an estimated $16.4K and bringing the position to 3,347 shares worth $1.75M. The position accounts for 0.34% of the portfolio, ranked #53.

Baker Tilly Wealth Management first reported a position in VRTX in Q3 2021 and has held it in 21 quarters since. The position peaked at $3.43M in Q2 2023. 1,161 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Baker Tilly Wealth Management held 3,347 shares of Vertex Pharmaceuticals worth $1.75M as of Q3 2026.
  • Baker Tilly Wealth Management bought 32 Vertex Pharmaceuticals shares in Q3 2026, an estimated $16.4K.
  • Vertex Pharmaceuticals made up 0.34% of Baker Tilly Wealth Management's portfolio in Q3 2026, its #53 holding.
  • Baker Tilly Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 21 quarters since.
  • Baker Tilly Wealth Management's Vertex Pharmaceuticals position peaked at $3.43M in Q2 2023.
  • 1,161 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Baker Tilly Wealth Management's 13F filing for Q3 2026, filed 5 Oct 2026.